PURPOSE: Investigate ErbB family expression in colorectal cancer patients with higher risk of recurrence after surgical treatment. METHODS: We studied 109 individuals with high risk stage II and stage III patients submitted to radical surgery. ErbB expression was assessed by tissue microarray technique. RESULTS: The immunohistochemical expression was considered positive for EGFR, ErbB2, ErbB3, ErbB4 membrane, and ErbB4 cytoplasmic in respectively 57.8%, 8.3%, 69.7%, 11%, and 19.3% of patients. ErbB3 negative expression was associated with lymphovascular invasion. EGFR, ErbB2, and cytoplasmic ErbB4 expression was not associated with prognosis. Membranous positive ErbB4 expression was an independent prognostic factor for recurrence. ErbB3 negative expression was an independent prognostic factor for recurrence and survival in the multivariate analysis. CONCLUSIONS: The immunohistochemical expression of ErbB3 and ErbB4 may identify a subgroup with stage II and III colorectal cancer at higher risk of recurrence.
PURPOSE: Investigate ErbB family expression in colorectal cancerpatients with higher risk of recurrence after surgical treatment. METHODS: We studied 109 individuals with high risk stage II and stage III patients submitted to radical surgery. ErbB expression was assessed by tissue microarray technique. RESULTS: The immunohistochemical expression was considered positive for EGFR, ErbB2, ErbB3, ErbB4 membrane, and ErbB4 cytoplasmic in respectively 57.8%, 8.3%, 69.7%, 11%, and 19.3% of patients. ErbB3 negative expression was associated with lymphovascular invasion. EGFR, ErbB2, and cytoplasmic ErbB4 expression was not associated with prognosis. Membranous positive ErbB4 expression was an independent prognostic factor for recurrence. ErbB3 negative expression was an independent prognostic factor for recurrence and survival in the multivariate analysis. CONCLUSIONS: The immunohistochemical expression of ErbB3 and ErbB4 may identify a subgroup with stage II and III colorectal cancer at higher risk of recurrence.
Authors: H Moch; P Schraml; L Bubendorf; M Mirlacher; J Kononen; T Gasser; M J Mihatsch; O P Kallioniemi; G Sauter Journal: Am J Pathol Date: 1999-04 Impact factor: 4.307
Authors: C C Compton; L P Fielding; L J Burgart; B Conley; H S Cooper; S R Hamilton; M E Hammond; D E Henson; R V Hutter; R B Nagle; M L Nielsen; D J Sargent; C R Taylor; M Welton; C Willett Journal: Arch Pathol Lab Med Date: 2000-07 Impact factor: 5.534
Authors: Ismaël Hervé Koumakpayi; Jean-Simon Diallo; Cécile Le Page; Laurent Lessard; Martin Gleave; Louis R Bégin; Anne-Marie Mes-Masson; Fred Saad Journal: Clin Cancer Res Date: 2006-05-01 Impact factor: 12.531
Authors: Gennaro Galizia; Eva Lieto; Francesca Ferraraccio; Ferdinando De Vita; Paolo Castellano; Michele Orditura; Vincenzo Imperatore; Anna La Mura; Giovanni La Manna; Margherita Pinto; Giuseppe Catalano; Carlo Pignatelli; Fortunato Ciardiello Journal: Ann Surg Oncol Date: 2006-04-18 Impact factor: 5.344
Authors: Hanna Styczen; Iris Nagelmeier; Tim Beissbarth; Manuel Nietert; Kia Homayounfar; Thilo Sprenger; Ute Boczek; Kathrin Stanek; Julia Kitz; Hendrik A Wolff; B Michael Ghadimi; Peter Middel; Torsten Liersch; Josef Rüschoff; Lena-Christin Conradi Journal: Oncotarget Date: 2015-06-20